LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Lakefront Biotherapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$29.79−0.11 (-0.37%)
Close on Oct 19, 2026
Share price
−$4.72 (−13.68%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Lakefront Biotherapeutics NV grew revenue 303.5% to €1.11B over fiscal 2025. Free cash flow was -€271.16M.
Revenue
€1.11B
+303.5% vs. a year earlier
Operating income
€295.04M
FY2025
Free cash flow
-€271.16M
FY2025
EPS, diluted
4.87 EUR
+334.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €1.11B
- Net income
- €320.88M
- EPS, diluted
- 4.87 EUR
- Free cash flow
- -€271.16M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
€1.11B+303.5% YoY
Gross profit
€1.08B+349.6% YoY
Operating income
€295.04M
Net income
€320.88M+333.1% YoY
EPS, diluted
4.87 EUR+334.8% YoY
Free cash flow
-€271.16M
Reported period